|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.44 USD | -1.86% |
|
-9.87% | -21.26% |
| 07/03 | UroGen Pharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| 02/03 | UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Capitalization | 90Cr 78Cr 71Cr 68Cr 123.35Cr 8.3TCr 128.22Cr 846.89Cr 335.61Cr 3.97TCr 336.86Cr 329.74Cr 14TCr | P/E ratio 2026 * |
-16.5x | P/E ratio 2027 * | 17.6x |
|---|---|---|---|---|---|
| Enterprise value | 74Cr 65Cr 59Cr 56Cr 101.96Cr 6.86TCr 105.99Cr 700.06Cr 277.43Cr 3.28TCr 278.46Cr 272.57Cr 12TCr | EV / Sales 2026 * |
3.03x | EV / Sales 2027 * | 1.67x |
| Free-Float |
90.82% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: UroGen Pharma Ltd.
| 1 day | -1.86% | ||
| 1 week | -9.87% | ||
| Current month | -15.02% | ||
| 1 month | -8.26% | ||
| 3 months | -15.41% | ||
| 6 months | -1.86% | ||
| Current year | -21.26% |
| 1 week | 17.94 |  | 21.06 |
| 1 month | 17.94 | | 22.5 |
| Current year | 17.94 | | 24.1 |
| 1 year | 3.42 | | 30 |
| 3 years | 3.42 | | 30 |
| 5 years | 3.42 | | 30 |
| 10 years | 3.42 | | 69.57 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 03/01/2019 | |
| Director of Finance/CFO | 46 | 08/10/2024 | |
Jason Smith
CMP | Compliance Officer | 54 | 09/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Arie Belldegrun
CHM | Chairman | 76 | 01/10/2012 |
Stuart Holden
BRD | Director/Board Member | 84 | 01/12/2015 |
Cynthia Butitta
BRD | Director/Board Member | 71 | 01/10/2017 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.86% | -9.87% | +69.17% | +95.13% | 90Cr | |
| -0.36% | -1.35% | +14.77% | +88.22% | 4.3TCr | |
| -1.13% | -2.60% | +48.72% | +15.07% | 3.92TCr | |
| -0.01% | -0.45% | +85.83% | +661.46% | 3.01TCr | |
| +1.21% | -10.16% | -6.44% | -29.73% | 2.19TCr | |
| -1.71% | -5.01% | +48.15% | -31.24% | 1.82TCr | |
| -2.18% | -1.50% | +24.54% | -31.71% | 1.6TCr | |
| -0.81% | +2.70% | +55.65% | +177.93% | 1.3TCr | |
| +4.27% | +6.68% | -16.00% | +953.59% | 1.25TCr | |
| +1.75% | +2.23% | +65.88% | - | 1.18TCr | |
| Average | -0.08% | -1.70% | +39.03% | +210.97% | 2.07TCr | |
| Weighted average by Cap. | -0.18% | -1.37% | +36.88% | +189.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24Cr 21Cr 19Cr 18Cr 34Cr 2.26TCr 35Cr 230.68Cr 91Cr 1.08TCr 92Cr 90Cr 3.9TCr | 43Cr 37Cr 34Cr 32Cr 58Cr 3.93TCr 61Cr 400.96Cr 158.9Cr 1.88TCr 159.49Cr 156.12Cr 6.78TCr |
| Net income | -5.61Cr -4.9Cr -4.43Cr -4.24Cr -7.7Cr -518.66Cr -8.01Cr -53Cr -21Cr -247.79Cr -21Cr -21Cr -894.99Cr | 8.46Cr 7.4Cr 6.68Cr 6.39Cr 12Cr 782.56Cr 12Cr 80Cr 32Cr 373.87Cr 32Cr 31Cr 1.35TCr |
| Net Debt | -16Cr -14Cr -12Cr -12Cr -21Cr -1.44TCr -22Cr -146.83Cr -58Cr -687.75Cr -58Cr -57Cr -2.48TCr | -19Cr -17Cr -15Cr -14Cr -26Cr -1.75TCr -27Cr -178.45Cr -71Cr -835.88Cr -71Cr -69Cr -3.02TCr |
Employees
291
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 18.44 $ | -1.86% | 7,86,244 |
| 12/26/12 | 18.79 $ | -0.27% | 6,36,476 |
| 11/26/11 | 18.84 $ | -3.14% | 4,53,053 |
| 10/26/10 | 19.45 $ | -2.31% | 4,74,195 |
| 09/26/09 | 19.91 $ | -2.69% | 8,78,828 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.44USD
Average target price
35.62USD
Spread / Average Target
+93.19%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- URGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition